Tuesday, 25 Feb 2020

You are here

Low Risk of Serious Complications with Meniscectomy

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days.

They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Serious complications occurred in 0·327% of cases, including 546 pulmonary embolisms (0·078%) and 944 infections necessitating further surgery (0·135%).  

For every 1390 fewer knee arthroscopies done, one pulmonary embolism could be prevented. For every 749 fewer procedures done, one native knee joint infection could be prevented.

Risk factors for serious complications included increasing age (adjusted odds ratio [aOR] 1·247 per decade [95% CI 1·208–1·288), higher modified Charlson comorbidity index (aOR 1·860 per 10 units).

Lower risks were seen in females (aOR 0·640) and risk of mortality fell over time. Serious complications, like death, myocardial infarction, and stroke occurred less frequently in the study cohort than in the general population.

The risks associated with arthroscopic meniscectomy were low, occasionally serious and have not changed with time.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

JAK Inhibitors Stimulate Osteoblasts

Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).

JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling RA inflammation and other clinical features.

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial.